



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/763,339	01/26/2004	Shawn R. Feaster	034047.003D1V1 (W 00-23B)	7108
53502	7590	01/28/2010		
OFFICE OF THE STAFF JUDGE ADVOCATE (SKS) U.S. ARMY MED. RESEARCH & MATERIEL COMMAND 504 SCOTT STREET ATTN: MCMR-ZA-J (MS. ELIZABETH ARWINE) FORT DETRICK, MD 21702-5012			EXAMINER	
			SHEN, BIN	
			ART UNIT	PAPER NUMBER
			1657	
		MAIL DATE	DELIVERY MODE	
		01/28/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Application No.	Applicant(s)
		10/763,339	FEASTER ET AL.
Examiner		Art Unit	
BIN SHEN		1657	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 09 December 2009.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 29-36,39 and 40 is/are pending in the application.

4a) Of the above claim(s) 31-34 and 36 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 29-30, 35, 39, 40 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/SB/06)
 Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____

5) Notice of Informal Patent Application

6) Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on Dec. 9, 2009 has been entered.

Status of the Claims

Claims 29-36, 39, 40 are currently pending. Claims 31-34, 36 are withdrawn from further consideration.

Claims 29, 30, 35, 39, 40 are presented for examination on the merits.

Benefit of priority is to 5/5/2000.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 29, 30, 35, 39 are rejected under 35 U.S.C. 102(b) as being anticipated by London (1995).

London teaches a field kit for estimation of cholinesterase in whole blood (page 59, left column, 2nd full paragraph).

Therefore, London teaches a device for detecting, measuring or monitoring cholinesterase in blood sample comprising a cartridge (read as kit) with plurality of substrates (page 59, left column, 2nd full paragraph, lines 1-3; a detector for detecting reaction rates (colorimeter, page 59, left column, 2nd full paragraph, line 5); software for calculating protein concentration (page 59,

left column, 2nd full paragraph, line 5, **Claim 29**); the cartridge/kit comprises reagent, buffer standard for measuring the reaction rates (see substrate for the enzymes on page 59, left column, 2nd full paragraph, lines 1-3, since the field kit estimate cholinesterase therefore inherently contains all necessary reagent/buffer/standard for measuring the reaction rates, **Claim 30**); wherein the kit is capable of detecting cholinesterase including plasma cholinesterase and erythrocyte cholinesterase (plurality of proteins, page 59, left column, 2nd full paragraph, lines 1-2, **Claim 35**); the field kit (Test-Mate OP kit, page 57, right column, 3rd full paragraph, lines 8-9) is inherently hand-held for easy application (**Claim 39**).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 29, 40 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combination of London and Jacobs (1993).

London's teachings anticipate claims 29 as above.

London does not teach cartridge triggers device automation when inserted.

Jacobs teaches a blood analyzer with an insertable cartridge (page 1891, left column, 1st full paragraph).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify/automate the device of London by using a insertable cartridge to trigger the automation of the device (**Claim 40**) because Jacobs teaches a cartridge that can be inserted in the device. One would have been motivated to automate the device because Jacobs et al. specifically described a cartridge in a blood analyzer and one of ordinary skill in the art has good reason to automate the device by trigger the automation by inserting the cartridge for anticipated success in view of Jacob's teaching of an insertable cartridge for a blood analyzer.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Conclusion

No claim is allowed.

Any inquiry concerning rejections or objections in this communication or earlier communications from the examiner should be directed to Bin Shen, whose telephone number is (571) 272-9040. The examiner can normally be reached on Monday through Friday, from about 9:00 AM to about 5:30 PM. A phone message left at this number will be responded to as soon as possible (i.e., shortly after the examiner returns to her office).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached at (571) 272-0925.

B Shen
Art Unit 1657

/Karen Cochrane Carlson/

Primary Examiner, Art Unit 1656